questionsmedicales.fr
Comportement et mécanismes comportementaux
Pulsion
Besoin impérieux
Besoin impérieux : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Besoin impérieux : Questions médicales les plus fréquentes",
"headline": "Besoin impérieux : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Besoin impérieux : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-02",
"dateModified": "2025-02-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Besoin impérieux"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pulsion",
"url": "https://questionsmedicales.fr/mesh/D004328",
"about": {
"@type": "MedicalCondition",
"name": "Pulsion",
"code": {
"@type": "MedicalCode",
"code": "D004328",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "F01.658.293"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Besoin impérieux",
"alternateName": "Craving",
"code": {
"@type": "MedicalCode",
"code": "D066249",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Michael A Sayette",
"url": "https://questionsmedicales.fr/author/Michael%20A%20Sayette",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."
}
},
{
"@type": "Person",
"name": "Kathleen A Garrison",
"url": "https://questionsmedicales.fr/author/Kathleen%20A%20Garrison",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA."
}
},
{
"@type": "Person",
"name": "Matthew C Enkema",
"url": "https://questionsmedicales.fr/author/Matthew%20C%20Enkema",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychology, University of Washington."
}
},
{
"@type": "Person",
"name": "Kevin A Hallgren",
"url": "https://questionsmedicales.fr/author/Kevin%20A%20Hallgren",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, University of Washington."
}
},
{
"@type": "Person",
"name": "Mary E Larimer",
"url": "https://questionsmedicales.fr/author/Mary%20E%20Larimer",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, University of Washington."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Ebolavirus Species-Specific Interferon Antagonism Mediated by VP24.",
"datePublished": "2023-04-28",
"url": "https://questionsmedicales.fr/article/37243162",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/v15051075"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of dimethyl fumarate and interferon outcomes in an MS cohort.",
"datePublished": "2022-07-11",
"url": "https://questionsmedicales.fr/article/35820822",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12883-022-02761-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Macrophage fumarate hydratase restrains mtRNA-mediated interferon production.",
"datePublished": "2023-03-08",
"url": "https://questionsmedicales.fr/article/36890227",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41586-023-05720-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "USP26 suppresses type I interferon signaling by targeting TRAF3 for deubiquitination.",
"datePublished": "2024-07-26",
"url": "https://questionsmedicales.fr/article/39058724",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0307776"
}
},
{
"@type": "ScholarlyArticle",
"name": "Interferon-β promotes the survival and function of induced regulatory T cells.",
"datePublished": "2022-08-29",
"url": "https://questionsmedicales.fr/article/36049243",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cyto.2022.156009"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Comportement et mécanismes comportementaux",
"item": "https://questionsmedicales.fr/mesh/D001520"
},
{
"@type": "ListItem",
"position": 3,
"name": "Pulsion",
"item": "https://questionsmedicales.fr/mesh/D004328"
},
{
"@type": "ListItem",
"position": 4,
"name": "Besoin impérieux",
"item": "https://questionsmedicales.fr/mesh/D066249"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Besoin impérieux - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Besoin impérieux",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Besoin impérieux",
"description": "Comment diagnostiquer un besoin impérieux ?\nQuels outils sont utilisés pour le diagnostic ?\nLe besoin impérieux est-il un trouble mental ?\nQuels critères DSM sont liés au besoin impérieux ?\nPeut-on mesurer l'intensité du craving ?",
"url": "https://questionsmedicales.fr/mesh/D066249?mesh_terms=Interferon-beta&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Besoin impérieux",
"description": "Quels sont les symptômes du besoin impérieux ?\nLe besoin impérieux peut-il causer de l'anxiété ?\nY a-t-il des symptômes physiques associés ?\nLe craving est-il constant ou intermittent ?\nComment le craving affecte-t-il le comportement ?",
"url": "https://questionsmedicales.fr/mesh/D066249?mesh_terms=Interferon-beta&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Besoin impérieux",
"description": "Comment prévenir le besoin impérieux ?\nLes programmes de sensibilisation sont-ils efficaces ?\nLe développement de compétences aide-t-il ?\nLes groupes de soutien sont-ils utiles ?\nLa gestion des déclencheurs est-elle importante ?",
"url": "https://questionsmedicales.fr/mesh/D066249?mesh_terms=Interferon-beta&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Besoin impérieux",
"description": "Quels traitements sont efficaces contre le craving ?\nLa thérapie cognitivo-comportementale aide-t-elle ?\nLes médicaments peuvent-ils réduire le craving ?\nLe soutien social est-il important dans le traitement ?\nY a-t-il des approches alternatives au traitement ?",
"url": "https://questionsmedicales.fr/mesh/D066249?mesh_terms=Interferon-beta&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Besoin impérieux",
"description": "Quelles complications peuvent survenir avec le craving ?\nLe craving peut-il mener à des addictions ?\nY a-t-il des risques physiques associés au craving ?\nLe besoin impérieux affecte-t-il les relations ?\nLe craving peut-il entraîner des problèmes juridiques ?",
"url": "https://questionsmedicales.fr/mesh/D066249?mesh_terms=Interferon-beta&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Besoin impérieux",
"description": "Quels sont les facteurs de risque du craving ?\nLe stress augmente-t-il le risque de craving ?\nLes troubles mentaux sont-ils des facteurs de risque ?\nL'environnement social influence-t-il le craving ?\nLes habitudes de vie jouent-elles un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D066249?mesh_terms=Interferon-beta&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un besoin impérieux ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation des symptômes et des antécédents du patient."
}
},
{
"@type": "Question",
"name": "Quels outils sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des questionnaires standardisés et des entretiens cliniques sont souvent utilisés."
}
},
{
"@type": "Question",
"name": "Le besoin impérieux est-il un trouble mental ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être associé à des troubles comme l'addiction ou les troubles alimentaires."
}
},
{
"@type": "Question",
"name": "Quels critères DSM sont liés au besoin impérieux ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères DSM-5 pour les troubles liés à des substances incluent le craving."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'intensité du craving ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des échelles de mesure spécifiques évaluent l'intensité du craving."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes du besoin impérieux ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent une envie intense, agitation, et parfois des symptômes physiques."
}
},
{
"@type": "Question",
"name": "Le besoin impérieux peut-il causer de l'anxiété ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le craving peut entraîner une anxiété significative chez les individus concernés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes physiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la transpiration ou des palpitations peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le craving est-il constant ou intermittent ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être intermittent, souvent déclenché par des stimuli environnementaux."
}
},
{
"@type": "Question",
"name": "Comment le craving affecte-t-il le comportement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut mener à des comportements compulsifs pour satisfaire l'envie."
}
},
{
"@type": "Question",
"name": "Comment prévenir le besoin impérieux ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par l'éducation, la gestion du stress et le soutien social."
}
},
{
"@type": "Question",
"name": "Les programmes de sensibilisation sont-ils efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils aident à informer sur les risques et à réduire le craving."
}
},
{
"@type": "Question",
"name": "Le développement de compétences aide-t-il ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, développer des compétences d'adaptation peut réduire le risque de craving."
}
},
{
"@type": "Question",
"name": "Les groupes de soutien sont-ils utiles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils offrent un environnement de soutien pour partager des expériences."
}
},
{
"@type": "Question",
"name": "La gestion des déclencheurs est-elle importante ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, identifier et gérer les déclencheurs peut prévenir le craving."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces contre le craving ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies comportementales et les médicaments peuvent aider à réduire le craving."
}
},
{
"@type": "Question",
"name": "La thérapie cognitivo-comportementale aide-t-elle ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est efficace pour modifier les pensées et comportements liés au craving."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils réduire le craving ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments, comme les antidépresseurs, peuvent diminuer le craving."
}
},
{
"@type": "Question",
"name": "Le soutien social est-il important dans le traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le soutien social joue un rôle crucial dans la gestion du craving."
}
},
{
"@type": "Question",
"name": "Y a-t-il des approches alternatives au traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches comme la méditation et la pleine conscience peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le craving ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles de santé mentale et des comportements à risque."
}
},
{
"@type": "Question",
"name": "Le craving peut-il mener à des addictions ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un besoin impérieux non traité peut évoluer vers une addiction sévère."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques physiques associés au craving ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le craving peut entraîner des comportements nuisibles à la santé physique."
}
},
{
"@type": "Question",
"name": "Le besoin impérieux affecte-t-il les relations ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut nuire aux relations personnelles et professionnelles."
}
},
{
"@type": "Question",
"name": "Le craving peut-il entraîner des problèmes juridiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des comportements impulsifs liés au craving peuvent causer des problèmes juridiques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque du craving ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le stress et l'environnement social sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "Le stress augmente-t-il le risque de craving ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress est un facteur majeur qui peut intensifier le besoin impérieux."
}
},
{
"@type": "Question",
"name": "Les troubles mentaux sont-ils des facteurs de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles comme l'anxiété et la dépression augmentent le risque de craving."
}
},
{
"@type": "Question",
"name": "L'environnement social influence-t-il le craving ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un environnement social négatif peut exacerber le besoin impérieux."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie jouent-elles un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie malsaines peuvent augmenter le risque de craving."
}
}
]
}
]
}
Members of the Ebolavirus genus demonstrate a marked differences in pathogenicity in humans with Ebola (EBOV) being the most pathogenic, Bundibugyo (BDBV) less pathogenic, and Reston (RESTV) is not kn...
To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients with relapsing-remitting Multiple Sclerosis (MS)....
Clinical and imaging data from patients treated with either IFNβ-1a or DMF for at least one year were reviewed. The proportion of patients with at least one clinical relapse within 3-15 months after t...
Three hundred sixteen (98 on IFNβ-1a, 218 on DMF) subjects were included. Baseline demographics were comparable between groups except for age, disease duration, and the number of previous treatments b...
DMF was associated with less clinical and radiological disease activity compared to IFNβ-1a....
Metabolic rewiring underlies the effector functions of macrophages...
Deubiquitinating enzymes (DUBs) play a pivotal role in regulating the antiviral immune response by targeting members of the RLR signaling pathway. As a pivotal member of the RLR pathway, TRAF3 is esse...
Type I interferons (IFNs) are pleiotropic cytokines and impact various immune cells, including regulatory T cells (Treg cells). The effect of type-I IFNs on the development and function of Treg cells ...
Oncogene-induced senescence (OIS) arrests cell proliferation in response to replication stress (RS) induced by oncogenes. OIS depends on the DNA damage response (DDR), but also on the cGAS-STING pathw...
Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS....
Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other ...
In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those ...
Interferons (IFNs) are pleiotropic cytokines originally identified for their antiviral activity. IFN-α and IFN-β are both type I IFNs that have been used to treat neurological diseases such as multipl...
Multiple sclerosis (MS) is an inflammatory disease characterized by damage to the myelin sheath surrounding axons in the central nervous system. While the exact mechanism of this destruction is unknow...
Cytosolic RNA sensing can elicit immune responses against viral pathogens. However, antiviral responses must be tightly regulated to avoid the uncontrolled production of type I interferons (IFN) that ...
The expression levels of IFN-β, IFIT1, and IFIT2 mRNA were determined by RT-PCR. The expression levels of p-IRF3, IRF3, RIG-I, MAVS, and MST4 proteins were determined by Western blot. The effect of se...
In this study, we reported that MST4 can act as a negative regulator of type I IFN production. Ectopic expression of MST4 suppressed the Poly (I:C) (polyino-sinic-polycytidylic acid)- and Sendai virus...
Our findings showed that MST4 acted as a crucial negative regulator of RLR-mediated type I IFN production. Video Abstract....